|
Synonyms: LJM716 | NVS201010
Compound class:
Antibody
Comment: Elgemtumab is a fully human anti-ERBB3 (HER3) investigational monoclonal antibody, with antineoplastic potential.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Protein BLAST alignment reveals that 100% matched peptide sequences for elgemtumab are contained in patent US8735551 B2 [1]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Garner AP, Sprague EAR, Ettenberg SA, Kunz C, Haubst N, Elis W. (2014)
Antibodies for epidermal growth factor receptor 3 (HER3). Patent number: US8735551 B2. Assignee: Novartis Ag.. Priority date: 20/08/2010. Publication date: 27/05/2014. |
